Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12 weeks versus 24 weeks of adjuvant oxaliplatin-based chemotherapy for resected stage III colon cancer
ACTRN12609000662268Phase 3Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Apr 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, capecitabine and folinic acid in colon cancer, sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Disease-free survival. Started Apr 2010; status: completed.
02
Drugs
oxaliplatinfluorouracilcapecitabinefolinic acid
03
Conditions
colon cancer
Beyond the preview
Go deeper on ACTRN12609000662268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000662268.